The Artisan Group

Singapore healthcare management
& medical specialists.

About

our mission

We provide artisanal, high-quality, patient-centric medical care and a smooth patient experience to patients in Singapore and the region.

Our Team

30 Staffs

Expertise

7 Clinics

Experience

Since 2019

From one small aesthetic clinic, we are now a proud team of 30 staffs & 8 doctors.

Our vision is to become a world class medical group in ASIA originating from Singapore.

Currently each of our business under the umbrella of The Artisan Group serves different aspects of medical care services with the same mission — Providing artisanal, top-in-class medical care to patients in Singapore and the region.

As our clinics grow, we hope to bring more value to the community, by bringing in improved healthcare services, machines, talents; providing better patients experience and satisfaction.

Exciting News: Artisan Clinic Hibiya Launches in Japan!

New Horizons in Regenerative Medicine: Now in Japan!

We’re excited to announce the opening of our new clinic in Japan, specializing in advanced regenerative medicine to bring cutting-edge care to more patients.

It is my honour and pleasure to introduce this expanding medical group in Singapore that is committed to providing top-notch healthcare services to the community.

Jamie Yeo

singapore celebrity (ex-DJ, actress, TV host)

About

Latest Achievements

Denza Machine

WORLD'S FIRST, WORLDS AHEAD — Monopolar + Bipoloar radiofrequency with sequential pulsing technology, a Game-Changing RF Skin Tightening* Device. The Artisan Clinic is proud to be the first in Asia to offer Denza.

DermaV Laser Machine

Lutronic APAC chose The Artisan Group to launch the FIRST DermaV Laser in August 2023 in Singapore and Malaysia, ensuring our patients get the latest medical aesthetic technology

HydraFacial Syndeo Machine

Top 5 clinics in SEA chosen to launch this latest advanced version of HydraFacial USA in 2023.

PicoSure Pro Machine

First PicoSure Pro (300k USD) in Asia in March 2022. Second PicoSure Pro in the same clinic in July 2023.

Microneedling Machine | Potenza™ | Cynosure

First Potenza in Asia in March 2021.

Hyperbaric Oxygen Therapy Chamber

Artisan Regenerative offering HBOT in Mar 2025.

Clinical Research

Hong, Gi-Woong MD, PhD^*; Wong, Isaac Kai Jie MD^†; Byungki, Cho MD^‡; Yoon, Song Eun MD^§; Song, Jong Keun MD^‖; Haykal, Diala MD^¶; Wan, Jovian MBChB^#; Kim, Jin-Hyun MD^**; Yi, Kyu-Ho MD, PhD^**,††Nasolabial folds significantly impact facial appearance and are a common aesthetic concern. This article reviews anatomic considerations and filler injection techniques for treating these folds, with a focus on the Korean population. The dermal filler used in this study is Maili hyaluronic acid filler (Sinclair Pharma), derived from a novel proprietary manufacturing technology known as OxiFree™ technology (Kylane Laboratoires , Switzerland).

The study analyzes various injection techniques, including needle-based and cannula-based approaches, with emphasis on safe and effective practices such as the Fern leaf and Duck walk techniques. A layered injection approach addressing both superficial and deep tissue planes is examined.

Three distinct types of nasolabial folds are identified: those caused by volume deficiency, tissue laxity, and muscular attachments. Each type requires a tailored treatment approach. It is not uncommon to find a combination of 2 of the types together in one person. The study highlights the importance of understanding anatomic variations, particularly the course of the facial artery in the Korean population, for safe injection practices.

A thorough understanding of nasolabial fold anatomy and appropriate treatment strategies is crucial for achieving optimal outcomes in aesthetic medicine. This is especially important for the nasolabial folds, which are highly mobile, and could easily cause misplaced dermal fillers to migrate. Future research on combination intervention techniques, including botulinum toxin, lipolytic agents, and thread-lifting, may further enhance overall treatment efficacy.

Kyu-Ho Yi, Isaac Kai Jie Wong, Jovian Wan

Background
Platysmal bands contribute to neck ageing and lower-face descent. Although botulinum toxin A (BoNT-A) is approved for this indication, conventional whole-muscle dosing requires many superficial injections with attendant risks.
‍
Objective
To develop an anatomically guided protocol that targets motor-dense zones of the platysma, optimizing efficacy while reducing dose and complications.
‍
Methods
Sihler-stained dissections mapped motor versus sensory innervation. Ultrasound-guided injections were performed in 40 patients, delivering 30–60 U BoNT-A per side at 15 sites concentrated in the upper two-thirds of the platysma and along the marginal mandibular border. Outcomes included band severity, jawline definition, adverse events, and cost.
‍
Results
Motor end-plates clustered in the upper platysma; the lower third was largely sensory. Targeted injections produced a ≥ 2-grade reduction in dynamic bands in 92.5% of patients by week 4, maintained through week 12. Mean toxin use fell 35% versus historical whole-muscle protocols; bruising dropped to 5%, with no dysphagia or lower-face weakness. Treatment costs were proportionally lower.
‍
Conclusions
Concentrating BoNT-A in the motor-rich upper platysma under ultrasound guidance maximizes aesthetic improvements while minimizing dose, discomfort and adverse events. This neural distribution-based algorithm offers a safer, more economical alternative to conventional platysmal band treatment.

Koppert, Erik MD^*; Wong, Isaac Kai Jie MD^†; Wan, Jovian MBChB^‡; Yoon, Song Eun MD^§; Song, Jong Keun MD^∥; Kim, Jin-Hyun MD^¶; Yi, Kyu-Ho MD, PhD^{¶,#

*Department of Surgery, Epworth Hawthorn and Epworth Eastern Private Hospitals, Melbourne, Victoria, Australia†The Artisan Clinic, Singapore, Singapore‡Medical Research Inc., Wonju, Korea§BRANDNEW Aesthetic Surgery Clinic∥Pixelab Plastic Surgery Clinic¶You and I clinic#Department of Oral Biology, Division of Anatomy and Developmental Biology, Human Identification Research Institute, BK21 FOUR Project, Yonsei University College of Dentistry, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, Korea}

Read pdf

‍You and I Clinic, Seoul, Korea
‍Kyu-Ho Yi

‍Division in Anatomy and Developmental Biology, Department of Oral Biology, Human Identification Research Institute, BK21 FOUR Project, Yonsei University College of Dentistry, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Korea
‍Kyu-Ho Yi

‍The Artisan Clinic, 435 Orchard Road, #20-03, Singapore, 238877, Singapore
‍Isaac Kai Jie Wong

‍Gaddiel Medical Group Limited, Tsim Sha Tsui, Hong Kong, China
‍Ka Fai Wong

‍EverKeen Medical Centre, Hong Kong, China
‍Kar Wai Alvin Lee

Read pdf

Download pdf

Wan, Jovian MBChB^*; Yoon, Song Eun MD^†; Song, Jong-Keun MD^‡; Wong, Isaac Kai Jie MD^§; Kim, Jin-Hyun MD^∥; Yi, Kyu-Ho MD, PhD^{∥,¶

*Medical Research Inc., Wonju, Korea†BRANDNEW Aesthetic Surgery Clinic‡Pixelab Plastic Surgery Clinic, Seoul, korea§The Artisan Clinic, Singapore∥You and I Clinic, Seoul, Korea¶Department of Oral Biology, Division of Anatomy and Developmental Biology, Human Identification Research Institute, BK21 FOUR Project, Yonsei University College of Dentistry, Seodaemun-gu, Seoul, KoreaAddress correspondence and reprint requests to Kyu-Ho Yi, MD, Department of Oral Biology, Division of Anatomy and Developmental Biology, Human Identification Research Institute, BK21 FOUR Project, Yonsei University College of Dentistry, Seoul, South Korea; E-mail: kyuho90@daum.netJ.W. and K.-H.Y.: conceptualization. J.W.: writing-original draft preparation. J.W., S.E.Y., J.K.S., I.K.J.W., J.-H.K., and K.-H.Y.: writing-review and editing. J.W. and K.-H.Y.: visualization. K.-H.Y.: supervision. All authors have reviewed and approved the article for submission.The authors report no conflicts of interest. This study was conducted in compliance with the principles set forth in the Declaration of Helsinki.Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal’s website, www.jcraniofacialsurgery.com.}^{The Journal of Craniofacial Surgery}^{():10.1097/SCS.0000000000011459, May 5, 2025. |}^DOI:^{10.1097/SCS.0000000000011459}

Background:
Atopic dermatitis (AD) is a chronic inflammatory skin condition that significantly impairs quality of life. Current therapies, including corticosteroids and calcineurin inhibitors, often provide incomplete relief or have undesirable side effects. Exosome-based therapies derived from adipose-derived mesenchymal stem cells (ADMSCs) offer a novel, multifaceted approach to addressing inflammation, skin barrier dysfunction, and pruritus, presenting a promising alternative for AD management.
‍
Objective:
This case series evaluates the efficacy and safety of ADMSC-derived exosome-based topical formulations (ZISHEL XOMAGE; Zishel Bio Inc., Seoul, Korea), in improving clinical and barrier-related outcomes in patients with moderate-to-severe facial AD.

Methods:
Twenty adults with moderate-to-severe facial AD (vIGA-AD scores 3–4) applied ADMSC-derived exosome twice daily for 6 weeks. Clinical assessments included vIGA-AD scores, transepidermal water loss (TEWL), and corneometry for hydration. Two blinded dermatologists independently assessed outcomes. Before-and-after photographs were taken under standardised conditions. Pruritus severity was evaluated using a visual analogue scale (VAS).

Results:
Eighty-five percent of patients achieved at least a 1-point reduction in vIGA-AD scores, with 50% achieving a 2-point reduction. Corneometry indicated a 58% improvement in hydration, while TEWL measurements demonstrated a 42% reduction, reflecting enhanced barrier integrity. Pruritus VAS scores declined by 70%. No adverse events were reported, and inter-rater reliability for vIGA-AD assessments was high (Cohen kappa=0.84). Representative cases highlighted substantial improvements in erythema, lichenification, and skin texture.

Conclusion:
ADMSC-derived exosome products showed significant efficacy in reducing AD severity and restoring barrier function, with excellent safety profiles. Larger, randomised controlled trials with extended follow-up are recommended to confirm these findings and establish these products as viable treatment options for AD.

Download pdf

By Wan, Jovian MBChB^*; Yoon, Song Eun MD^†; Pamela, Ruri MD^‡; Kai Jie Wong, Isaac MD^§; Vitale, Massimo MD^∥; Cartier, Hugues MD^¶; Garson, Sebastien MD^#; Yi, Kyu-Ho MD, PhD^**,††*Medical Research Inc., Wonju
†BRANDNEW Aesthetic Surgery Clinic, Seoul, Korea
‡CELV Dermatology Clinic, Jakarta, Indonesia
§The Artisan Clinic, Singapore
∥Private Practice, Bologna, Italy
¶Centre Médical Saint Jean, Arras, France
#Cabinet Médical, Senlis, France
**Division in Anatomy and Developmental Biology, Department of Oral Biology, Human Identification Research Institute, BK21 FOUR Project, Yonsei University College of Dentistry
††You and I Clinic, Seoul, Korea

Objective:
This case series evaluates the efficacy and safety of LDE therapy combined with microneedling in patients with active acne, PIH, and atrophic scarring.

Methods:
Three patients with moderate to severe acne [Investigator’s Global Assessment (IGA) scores 2–4], visible PIH, and atrophic scarring underwent biweekly microneedling treatments followed by topical application of LDE (BLESKIN EXXO, Daeyang Medical) over 2 months. Assessments were conducted at baseline and 2-month post-treatment, utilizing the IGA scale for acne severity, the Postinflammatory Hyperpigmentation Area and Severity Index (PIHASI) for PIH, and the Goodman and Baron Scarring Grading System for atrophic scarring. Two independent, blinded dermatologists evaluated clinical photographs and scored all outcomes. Patient satisfaction was recorded on a 10-point Likert scale.

Results:
All patients exhibited significant improvements in acne severity, PIH, and atrophic scarring. IGA scores decreased from baseline values of 3 to 4 to 1 to 2 post-treatment. PIHASI scores were reduced by 4 to 6 points, and Goodman and Baron scores improved by one grade level. Patient satisfaction scores ranged from 8 to 9 out of 10. Minimal adverse events were noted, with only one instance of transient erythema observed during the study.

Conclusion:
LDE therapy combined with microneedling seems to be a promising treatment modality for active acne, PIH, and atrophic scarring, demonstrating significant clinical improvements with high patient satisfaction and minimal adverse effects. Further research with larger cohorts and controlled studies is warranted to validate these findings...."

By Isaac Wong Kai Jie ^1, Kar Wai Alvin Lee ², Song Eun Yoon ³, Jong Keun Song ⁴, Lisa Kwin Wah Chan ⁵, Cheuk Hung Lee ⁶, Eunji Jeong ^7

1 The Artisan Clinic, Singapore
² EverKeen Medical Centre, Hong Kong
³ Brandnew Aesthetic Surgery Clinic, Seoul, Republic of Korea
⁴ Pixelab Plastic Surgery Clinic, Seoul, Republic of Korea
⁵ College of Medicine, Central Michigan University, Saginaw, MI, USA
⁶ You & I Clinic, Seoul, Republic of Korea
⁷ Division in Anatomy and Developmental Biology, Department of Oral Biology, Human Identification Research Institute, BK21 FOUR Project, Yonsei University College of Dentistry, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea* Author to whom correspondence should be addressed.